Pfizer Australia Pty Ltd

Tukysa (tucatinib) has been approved to be used in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2 positive unresectable or metastatic colorectal cancer.

Abrysvo is a vaccine that provides active immunisation for the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV).

Nurtec ODT (rimegepant) has been approved for the treatment of acute migraine and the prophylactic treatment of episodic migraine in adults

Comirnaty Omicron XBB.1.5 (raxtozinameran) COVID-19 vaccine has been approved for the prevention of COVID-19 in individuals 6 months to 12 years old.

Comirnaty Original/Omicron BA.4-5 (tozinameran/famtozinameran) is provisionally approved to prevent COVID-19 in individuals 5 years of age and older.

Comirnaty (tozinameran), a vaccine, has been approved for the prevention of coronavirus disease 2019 (COVID-19) in individuals 12 years of age and older.

AusPAR for full registration for COMIRNATY (tozinameran) for active immunisation to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.

AusPAR for Prevenar 20 (pneumococcal polysaccharide conjugate vaccine) for the prevention of pneumococcal disease caused by Streptococcus pneumoniae.

AusPAR for Comirnaty Original/Omicron BA.4-5 COVID-19 vaccine (tozinameran and famtozinam) for prevention of COVID-19.

AusPAR for Ngenla (somatrogon) for treatment of paediatric patients with growth disturbance due to insufficient growth hormone.